Investor Centre Archive - Alterity Therapeutics

Alterity receives a $4.8 million R&D Tax Incentive Refund

January 15, 2020January 15, 2020

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced that it has received a A$4.

European Commission approves Orphan Designation for Alterity’s lead drug candidate

January 14, 2020January 15, 2020

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces that the European Commission (EC) has

Alterity’s lead drug candidate receives positive opinion from European medical agency

November 18, 2019November 18, 2019

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has received a positive opinion from the Europe

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

September 25, 2019October 10, 2019

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), presents a poster today titled: A First in Hum

Alterity Therapeutics to Present at the Janney Healthcare Conference in New York

September 9, 2019September 9, 2019

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Janney Healthcare Confe

Quarterly Cash Flow Report

August 1, 2019August 1, 2019

Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

July 29, 2019July 29, 2019

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully comple

Alterity Therapeutics talks to Finance News Network

July 9, 2019July 9, 2019

Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug

Chairman’s Address to Shareholders 2019 Annual General Meeting

November 26, 2019November 26, 2019

Chairman’s Address to Shareholders 2019 AGM

November 26, 2019	AGM Presentation 2019	pdf	777 KB
June 4, 2019	Alterity Therapeutics Investor Presentation for FNN	pdf	1 MB
May 9, 2019	Alterity Therapeutics AAN Presentation	pdf	755 KB
April 10, 2019	Alterity Therapeutics Investor Presentation	pdf	2 MB
January 8, 2018	Prana Biotechnology JPM investor presentation	pdf	3 MB
January 8, 2018	Biotech Showcase Presentation	pdf	3 MB
January 8, 2018	Biotechnology Biotech Showcase Investor Presentation	pdf	3 MB
April 22, 2016	World Orphan Drug Congress Presentation	pdf	3 MB
July 17, 2014	AAIC Panel Presentation – Colin Masters	pdf	3 MB
February 18, 2014	Reach2HD Clinical Results Investor Presentation	pdf	1 MB

December 11, 2019	Upcoming release of warrants from voluntary escrow December 2019	pdf	149 KB
November 26, 2019	Results of AGM 2019	pdf	169 KB
November 26, 2019	Chairman’s Address 2019 AGM	pdf	156 KB
November 22, 2019	Appendix 3B – November 2019	pdf	344 KB
October 25, 2019	Notice of AGM 2019	pdf	1 MB
September 2, 2019	Alterity filed Form 20-F and XBRL data with the SEC 2019	pdf	158 KB
August 20, 2019	Notice of Change of Interests of Substantial Holder August 2019	pdf	1,006 KB
August 5, 2019	Upcoming Release of Shares from Voluntary Escrow – August 2019	pdf	266 KB
August 1, 2019	Appendix 3B – New Issue Announcement – August 2019	pdf	350 KB
August 1, 2019	Quarterly Cash Flow Report – June 2019	pdf	373 KB
July 29, 2019	Successful Completion of Phase 1 Clinical Trial – July 2019	pdf	201 KB
June 12, 2019	Alterity presents at the American Academy of Neurology	pdf	238 KB
June 12, 2019	Alterity commences US investor meetings 2019	pdf	205 KB
June 12, 2019	Becoming a substantial shareholder 2019	pdf	2 MB
June 12, 2019	Form 603 Notice lodged by Bank of New York Mellon	pdf	205 KB
June 12, 2019	Alterity Thereapeutics commences US investor meetings2019	pdf	205 KB
June 4, 2019	Notice of Ceasing to be a Substantial Holder ATH – June 2019	pdf	90 KB
June 4, 2019	Alterity Therapeutics Investor Presentation to Finance News Network Conference – Jun 2019	pdf	1 MB
May 23, 2019	Prospectus filed pursuant to SEC Rule 424(b)(3) – May 2019	pdf	433 KB
May 20, 2019	Upcoming Release of Shares from Escrow – May 2019	pdf	203 KB
May 14, 2019	Form F-3 – May 2019	pdf	857 KB
April 10, 2019	Becoming A Substantial Shareholder Alterity – Apr 2019	pdf	723 KB
April 10, 2019	Appendix 3X – Initial Directors Interest Notice DS – Apr 2019	pdf	125 KB
April 10, 2019	Appendix 3X – Initial Directors Interest Notice TE – Apr 2019	pdf	126 KB
April 10, 2019	Appendix 3Z – Final Directors Interest Notice IS – Apr 2019	pdf	127 KB
April 10, 2019	Appendix 3Z – Final Directors Interest Notice GM – Apr 2019	pdf	127 KB
April 10, 2019	Notice of Initial Substantial Holder Life Biosciences – Apr 2019	pdf	1 MB
March 21, 2019	Appendix 3B – Mar 2019	pdf	318 KB
March 6, 2019	Notice of General Meeting – Apr 2019	pdf	3 MB
March 5, 2019	Notice of General Meeting and Explanatory Memorandum – Mar 2019	pdf	3 MB
January 9, 2019	Notice of ceasing to be a substantial holder MUFG – Jan 2019	pdf	165 KB
January 9, 2019	Notice of Ceasing to be a Substantial Holder MS – Jan 2019	pdf	263 KB
January 7, 2019	Prana Biotechnology BSC Presentation – Jan 2019	pdf	1 MB

February 10, 2019	Appendix 3B – Cleansing Notice – Feb 2018	pdf	362 KB
January 7, 2019	Form 603 – Notice of Initial Substantial Holder Morgan Stanley – Jan 2018	pdf	543 KB
January 7, 2019	Form 603 – Notice of Initial Substantial Holder MUFG – Jan 2018	pdf	457 KB
January 7, 2019	Appendix 3B – Jan 2018	pdf	955 KB
December 23, 2018	PBT Trading Halt – Dec 2018	pdf	459 KB
December 4, 2018	Form S-8 Dec 2018	pdf	271 KB
November 19, 2018	Appendix 3B – Nov 2018	pdf	940 KB
November 19, 2018	Appendix 3Y Change of Director’s Interest Notice – Nov 2018	pdf	456 KB
November 16, 2018	Results of AGM 2018	pdf	186 KB
November 16, 2018	AGM Presentation – Nov 2018	pdf	621 KB
October 16, 2018	Notice of AGM – Oct 2018	pdf	849 KB
July 16, 2018	Appendix 3B and 708A Notice – Jul 2018	pdf	248 KB
June 27, 2018	Investor Presentation – Jun 2018	pdf	5 MB
January 22, 2018	Appendix 3B – Jan 2018	pdf	809 KB

June 7, 2017	Appendix 3B – Jun 2017	pdf	814 KB
June 26, 2017	Change of Address – June 2017	pdf	366 KB
September 26, 2017	Change of Address -Sept 2017	pdf	619 KB
October 11, 2017	Form F-3 Oct 2017	pdf	255 KB
October 16, 2017	Notice of AGM – Oct 2017	pdf	8 MB
November 9, 2017	Prospectus Supplement – Nov 2017	pdf	149 KB
November 9, 2017	Form 6-K Nov 2017	pdf	70 KB
November 17, 2017	Results of AGM 2017	pdf	92 KB
November 17, 2017	AGM Presentation 2017	pdf	980 KB
December 19, 2017	Appendix 3B – Dec 2017	pdf	810 KB
December 22, 2017	Appendix 3Y Change of Director’s Interest GPK – Dec 2017	pdf	534 KB
December 22, 2017	Appendix 3Y – Change of Director’s Interest BM – Dec 2017	pdf	533 KB
December 22, 2017	Appendix 3Y – Change of Director’s Interest GM – Dec 2017	pdf	533 KB
December 22, 2017	Appendix 3Y – Change of Director’s Interest LG – Dec 2017	pdf	532 KB
December 22, 2017	Appendix 3Y Change of Director’s Interest PM – Dec 2017	pdf	532 KB

March 29, 2016	PBT Completes Ratio Change on NASDAQ – Mar 2016	pdf	377 KB
April 22, 2016	Prana Presents at World Orphan Drug Congress – Apr 2016	pdf	3 MB
October 14, 2016	Form-6k Oct 2016	pdf	263 KB
October 14, 2016	Prospectus Supplement – Oct 2016	pdf	201 KB
October 14, 2016	Notice of AGM – Oct 2016	pdf	9 MB
November 17, 2016	Results of AGM – Nov 2017	pdf	65 KB
May 10, 2019	Prana Completes Ratio Change on NASDAQ – Mar 2016	pdf	377 KB

Investor Centre
Archive

Investor Resources

Investor presentations

ASX Announcements

Financial reports

Corporate governance

News